Orphan Drug Development Bottlenecks? Smarter CMC and Regulatory Solutions
Recognizing the early signs of issues in orphan drug development is crucial for effective intervention. Common symptoms may include:Click to read the full article.
PRODUCT TYPES
Radiopharmaceutical Production Failures? Safety, QC, and Release Solutions
Recognizing failure signals early in the radiopharmaceutical production process is essential for effective containment and risk management. Symptoms may manifest either in the manufacturing environment or during quality control assessments.Click…
Veterinary Product Compliance Problems? Labeling, Stability, and GMP Solutions
Identifying symptoms indicating compliance issues is the first step in addressing potential problems with veterinary medicines. Common signs that may signal underlying issues include:Click to read the full article.
Supplement Quality Variability Problems? Testing, Label Claims, and Compliance Solutions
Identifying symptoms of quality variability is the first step in addressing the underlying issues. Common signals that might indicate problems in nutraceutical manufacturing include:Click to read the full article.
Herbal Product Consistency Problems? Standardization and Quality Solutions
Identifying the early symptoms of inconsistency in herbal products is crucial for timely intervention. Common signals may include:Click to read the full article.
API co-crystal / salt form inconsistency after raw material supplier change: root cause analysis (process vs lab) with CAPA effectiveness checks
Initial indications of inconsistency in co-crystal or salt form may emerge through various symptoms evident on the manufacturing floor or in the laboratory analysis. Common signs to look out for…
API packaging moisture ingress issue after raw material supplier change: risk-based approach to prevent repeat OOS across future API batches
The identification of moisture ingress typically manifests through a variety of symptoms, including:Click to read the full article.
API starting material traceability gap during stability pull at 6/12 months: how to write a defensible deviation narrative for inspections
The first step in addressing any deviation related to API starting material traceability is the identification of symptoms or signals indicative of a potential gap. Such symptoms typically include:Click to…
API container closure compatibility failure during CPV trending review: supplier qualification gaps and incoming testing upgrades to close the loop
Detection of container closure compatibility issues during CPV trending can manifest through various symptoms. It's vital to monitor these signals early in the process to mitigate potential risks. Common symptoms…
API starting material traceability gap during EU GMP inspection preparation: how to justify reprocessing vs rejection to FDA/EMA inspectors
Identifying symptoms that indicate a traceability gap is the first step in responding effectively. Some signals may include:Click to read the full article.
API microbial limit failure during routine release testing: root cause analysis (process vs lab) with CAPA effectiveness checks
Identifying the symptoms of microbial limit failures is crucial in initiating an effective investigation. Symptoms may arise from various sources, including inconsistencies in data during routine testing or unexpected results…
API heavy metals / elemental impurities OOS during FDA inspection readiness: risk-based approach to prevent repeat OOS across future API batches
Understanding the symptoms or signals indicative of an OOS result for heavy metals is the first step in any deviation investigation. Symptoms may manifest through various channels in the manufacturing…